Bluebird bio Inc

Bluebird bio — EHA 2015

22 slides from Bluebird bio's conference presentation, Jun 15, 2015

  1. Slide 1: EHA 2015 Clinical Data Update

    Transforming the Lives of Patients with Severe Genetic and Rare Diseases EHA 2015 Clinical Data Update Making Hope a Reality Exhibit 99.3

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue

  3. Slide 3: bluebird bio: Why We Do What We Do

    bluebird bio: Why We Do What We Do Our Vision – Make Hope a Reality Seeking to transform the lives of patients with severe genetic and rare diseases through the development of innovative gene therapy products. Ethan Cameron Aidan

  4. Slide 4: bluebird Pipeline Overview

    bluebird Pipeline Overview Childhood Cerebral ALD β-thalassemia Major* Multiple Myeloma Lenti-D™ LentiGlobin® bb2121 BCMA Undisclosed + Gene Editing Product Candidates Severe Sickle Cell Disease Early Pipeline CNS Diseases Oncology Rare Hemoglobinopathies Research Multiple Myeloma Next Gen BCMA Five

  5. Slide 5: Recent Events and Milestones

    Recent Events and Milestones Accelerated regulatory pathway for LentiGlobin in β-thalassemia defined for U.S. and EU Achieved enrollment targets in Starbeam Study (CCALD) and Northstar Study (β-thalassemia major) Defined oncology strategy – BCMA 1st CAR T Program; Five Prime target; bluebird indepen

  6. Slide 6: New CSO Appointed

    New CSO Appointed 15 years of experience in biopharmaceutical industry Extensive gene therapy and genome editing experience Formerly Chief Scientific Officer and Senior Vice President of Research at Sangamo BioSciences D.Phil. in Biochemistry from Oxford University; B.Sc. in Microbiology from Sheffi

  7. Slide 7: EHA Data Update

    EHA Data Update

  8. Slide 8: Data Demonstrate Continued Promise of Gene Therapy in Beta-thalassemia Major

    Data Demonstrate Continued Promise of Gene Therapy in Beta-thalassemia Major; First Patient with Severe Sickle Cell Disease Treated with Gene Therapy EHA 2015: Updated data from three patients in HGB-205 Beta-thalassemia: As of May 2015, beta-thalassemia major Subjects 1201 and 1202 remained transfu

  9. Slide 9: HGB-205 Study Design

    HGB-205 Study Design β-thalassemia major Severe sickle cell disease Ages 5-35 Ages 5-35 Eligible to undergo HSCT, no matched related donor Eligible to undergo HSCT, no matched related donor ≥ 100 mL pRBCs/kg/year transfusion requirement Poor prognostic risk factors (e.g., multiple pain crises, acute

  10. Slide 10: Rationale for the Treatment of SCD with BB305 Gene Therapy

    Rationale for the Treatment of SCD with BB305 Gene Therapy Patients with SCD and hereditary persistence of fetal hemoglobin with HbF of 30% are typically asymptomatic despite HbS of 70% Patients with SCD are asymptomatic after allo-HSCT even with mixed donor chimerism of 15-20% While hydroxyurea is

  11. Slide 11: Demographics and Baseline Characteristics for Treated Patients

    Demographics and Baseline Characteristics for Treated Patients with β-thalassemia Major and Severe SCD TRIAL HGB-205 Disease Beta-thalassemia Major Severe SCD Patient 1201 1202 1204 Age/Sex 18/F 16/M 13/M Country of birth Syria France France Genotype β0/βE β0/βE βS/βS pRBC Transfusion requirement (m

  12. Slide 12: Clinical Safety for Infused Subjects

    Clinical Safety for Infused Subjects Disease Beta-thalassemia Major Severe SCD Patient 1201 1202 1204 Neutrophil engraftment Day + 13 Day + 15 Day + 37 Platelet engraftment Day + 17 Day + 24 Day + 91 Non-laboratory ≥Grade 3 AEs Mucositis Premature menopause Herpetic gingivostomatitis Mucositis None

  13. Slide 13: High and Persistent Levels of Integrated Virus in Peripheral Blood Leukocytes

    High and Persistent Levels of Integrated Virus in Peripheral Blood Leukocytes VCN (vector copies/diploid genome) Months post-drug product infusion *Subject 1202 nine month data not reported due to a sample-specific assay performance issue Drug substance VCN PBL VCN Subject 1202* Subject 1201 Subject

  14. Slide 14: Sustained High Production of HbAT87Q in Beta-thalassemia Major

    Sustained High Production of HbAT87Q in Both Subjects with β-thalassemia Major Hb g/dL Months post-drug product infusion Patient 1201 1202 Subject 1201 (female) producing 7.3 g/dL HbAT87Q at 15 months Subject 1202 (male) producing 9.7 g/dL HbAT87Q at 15 months HbAT87Q Hb A (transfused blood) Hb A2 H

  15. Slide 15: Transfusion Independence Sustained for More than One Year

    Transfusion Independence Sustained for More than One Year Days Transfusion-Free Months Post-drug Infusion Both 1201 and 1202 show stability or improvements in markers of dyserythropoiesis - LDH, reticulocyte count and erythroblast counts 1201 1202 0 1 2 3 4 5 6 7 8 9 10 16 11 12 13 14 15 14 months 1

  16. Slide 16: Anti-sickling Hemoglobin Accounts for 45% of Total Hemoglobin at Six Months

    Anti-sickling Hemoglobin (HbAT87Q + HbF) Accounts for 45% of Total Hemoglobin at Six Months Hb g/dL Months post-drug product infusion HbAT87Q Hb S Hb A2 Hb F Hb A Subject 1204 (βS/βS) producing 4.3 g/dL HbAT87Q (40%), 0.49 g/dL of HbF (5%) and 4.9 g/dL HbS (47%) at 6 months HbAT87Q + HbF = 45% 47% 4

  17. Slide 17: Clinical Outcomes of Subject with Severe SCD

    Clinical Outcomes of Subject with Severe SCD Transfusion History Hospitalization History Reticulocyte count LDH (normal 125-243 U/L) Weaned off transfusions; last transfusion on Day + 88 (> 3 months ago) 131.7 x 109/L No hospitalizations or acute SCD-related events since LentiGlobin BB305 Drug Produ

  18. Slide 18: HbAT87Q Increase in Subjects with Severe SCD and Beta-thalassemia Major

    HbAT87Q Increase in Subjects with Severe SCD and β‑thalassemia Major *Subject 1204 engrafted 3 weeks later than subjects 1201 and 1202 Subject 1201 Subject 1202 Subject 1204*

  19. Slide 19: Additional Update: First SCD Patient Infused in HGB-206

    Additional Update: First Sickle Cell Disease Patient Infused in HGB-206 Status Primary & Secondary Endpoints Open for enrollment Initial data expected in 2015 HGB-206 Study N=8 Patients with severe sickle cell disease Open label, multi-center, U.S.-based study Safety and efficacy among patients with

  20. Slide 20: Ongoing Studies Using LentiGlobin BB305 Drug Product

    Ongoing Studies Using LentiGlobin BB305 Drug Product Worldwide Study Centers Indication Planned subjects Current Status HGB-205 (trial reported today) 1 in France β-thalassemia major and severe sickle cell disease 7 7 subjects enrolled 3 subjects treated HGB-204 “Northstar Study” 4 in US 1 in Austra

  21. Slide 21: Recent Events and Milestones

    Recent Events and Milestones Accelerated regulatory pathway for LentiGlobin in β-thalassemia defined for U.S. and EU Achieved enrollment targets in Starbeam Study (CCALD) and Northstar Study (β-thalassemia major) Defined oncology strategy – BCMA 1st CAR T Program; Five Prime target; bluebird indepen

  22. Slide 22: Transforming the Lives of Patients with Severe Genetic and Rare Diseases

    Transforming the Lives of Patients with Severe Genetic and Rare Diseases Making Hope a Reality

bluebird bio — EHA 2015 on 6ix